11. Utilization of Mass Spectrometry for the Structural Characterization of Biopharmaceutical Protein Products

  1. Michael L. Gross2,
  2. Guodong Chen3 and
  3. Birendra N. Pramanik4
  1. Amareth Lim and
  2. Catherine A. Srebalus Barnes

Published Online: 23 SEP 2011

DOI: 10.1002/9781118116555.ch11

Protein and Peptide Mass Spectrometry in Drug Discovery

Protein and Peptide Mass Spectrometry in Drug Discovery

How to Cite

Lim, A. and Barnes, C. A. S. (2011) Utilization of Mass Spectrometry for the Structural Characterization of Biopharmaceutical Protein Products, in Protein and Peptide Mass Spectrometry in Drug Discovery (eds M. L. Gross, G. Chen and B. N. Pramanik), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9781118116555.ch11

Editor Information

  1. 2

    Washington University, St. Louis, MO, USA

  2. 3

    Bristol-Myers Squibb, Princeton, NJ, USA

  3. 4

    Merck Research Laboratories, Kenilworth, NJ, USA

Author Information

  1. Eli Lilly and Company, Indianapolis, IN, USA

Publication History

  1. Published Online: 23 SEP 2011
  2. Published Print: 21 OCT 2011

ISBN Information

Print ISBN: 9780470258170

Online ISBN: 9781118116555

SEARCH

Keywords:

  • protein structure characterization;
  • recombinant therapeutic proteins;
  • analytical control strategies

Summary

This chapter contains sections titled:

  • Introduction

  • MS-Based Approach for the Characterization of Recombinant Therapeutic Proteins

  • Cell Culture Development

  • Purification Development

  • Formulation Development

  • Analytical Method Development

  • Confirmation of Structure/Product Comparability Assessment

  • Conclusions

  • Acknowledgments

  • References